16.05.2012
Britain's drug watchdog has reversed a controversial decision not to fund a new prostate cancer pill that was developed in the country after maker Johnson & Johnson agreed a new discount on supplies to the UK state healthcare service.
Zytiga, which is known chemically as abiraterone, was approved last year in Europe and the United States to treat advanced prostate cancer in patients who previously received chemotherapy.
more10.05.2012
A U.S. Senate panel has launched a probe of possible links between three drugmakers and nonprofit medical groups that advocated for increasing the use of prescription painkillers, now the target of a nationwide law enforcement crackdown.
more26.04.2012
Johnson & Johnson is sending in a former Army Ranger to clean up several big messes that have hurt its reputation, earnings and share price in the past three years.
more10.04.2012
Cardinal Health has named a former longtime Johnson & Johnson executive as the new head for its $9 billion medical products and services business, the U.S. pharmaceutical wholesaler said on Tuesday.
Donald Casey replaces Mike Lynch, who Cardinal said was leaving to pursue his ambition to lead a company of his own in the Chicago area. Lynch will stay on at Cardinal on a part-time basis through September.
more05.04.2012
A raft of new medicines pushed U.S. spending on drugs modestly higher last year, but the gains were curbed by weak prescription use as Americans avoided doctor visits, according to a report released on Wednesday.
Overall U.S. spending on medicines reached $320 billion in 2011, up 3.7% from 2010, according to the report from IMS Health, a healthcare information and services company. The increase was just 0.5% on a per capita basis.
more02.04.2012
In a nondescript suburb south of London, tucked away behind a big hospital, Paul Workman and fellow scientists are celebrating victory in the "World Cup" of cancer drug research for their work in discovering a stream of new medicines.
But the win is bitter-sweet. One of the new drugs behind the coveted prize from the American Association for Cancer Research (AACR) has been deemed too costly to use in state-run British hospitals like the one next door.
It is a stark example of the pricing crisis now facing cancer medicines across the globe.
more03.11.2011
Viiv Healthcare, a GlaxoSmithKline and Pfizer joint venture, will start manufacturing HIV medicines in Russia in partnership with local drugmaker Binnopharm. Agreeing a local partnership is a way for international drug companies to secure guaranteed sales in Russia, which wants to reduce dependence on imported drugs. Global drugmakers have pledged at least $1 billion in investments in Russian manufacturing, packaging and research and development.
more10.08.2011
Healthcare giant Johnson & Johnson has reached an agreement to settle a single misdemeanor charge related to its antipsychotic treatment Risperdal, the company said in a regulatory filing Tuesday.
more20.07.2011
Johnson & Johnson reported that its second-quarter net earnings were $2.776 billion or $1 per share, down from $3.449 billion or $1.23 per share in the same quarter last year. Adjusted net earnings rose to $3.548 billion or $1.28 per share, from $3.382 billion or $1.21 per share in the year ago quarter. Analysts polled by Thomson Reuters expected the company to report earnings of $1.23 per share for the quarter.
more19.07.2011
Healthcare giant Johnson & Johnson's board of directors has agreed to the creation of a new regulatory and compliance committee to monitor oversight of compliance and quality issues, the Wall Street Journal reported Monday. However, the board reportedly decided not to pursue litigation filed by certain shareholders last year against certain company officials.
more